SG10201913497XA - Biopharmaceutical compositions and related methods - Google Patents

Biopharmaceutical compositions and related methods

Info

Publication number: SG10201913497XA
Authority: SG; Singapore
Prior art keywords: related methods; biopharmaceutical compositions; biopharmaceutical; compositions; methods
Prior art date: 2017-05-26

Application number

SG10201913497XA

Inventor

Steven Grant

Chika Akinseye

Tejinder Bhinder

Laura Hook

Alan Peter Lewis

Martin Orecchia

Original Assignee

Glaxosmithkline Ip Dev Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-26

Filing date

2018-05-24

Publication date

2020-02-27

2018-05-24 Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd

2020-02-27 Publication of SG10201913497XA publication Critical patent/SG10201913497XA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Immunology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG10201913497XA 2017-05-26 2018-05-24 Biopharmaceutical compositions and related methods SG10201913497XA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762511441P	2017-05-26	2017-05-26

Publications (1)

Publication Number	Publication Date
SG10201913497XA true SG10201913497XA (en)	2020-02-27

Family

ID=62683386

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201913497XA SG10201913497XA (en)	2017-05-26	2018-05-24	Biopharmaceutical compositions and related methods

Country Status (24)

Country	Link
US (3)	US10787509B2 (en)
EP (1)	EP3630824A1 (en)
JP (2)	JP7224304B2 (en)
KR (1)	KR102473898B1 (en)
CN (5)	CN117018188A (en)
AR (1)	AR111764A1 (en)
AU (2)	AU2018273174B2 (en)
BR (1)	BR112019024884A2 (en)
CA (1)	CA3064522A1 (en)
CL (1)	CL2019003418A1 (en)
CO (1)	CO2019013245A2 (en)
CR (1)	CR20190541A (en)
DO (1)	DOP2019000297A (en)
EA (1)	EA201992802A1 (en)
IL (1)	IL270719B2 (en)
MX (1)	MX2019014105A (en)
MY (1)	MY200912A (en)
NZ (1)	NZ760380A (en)
PE (1)	PE20191844A1 (en)
PH (1)	PH12019502619A1 (en)
SG (1)	SG10201913497XA (en)
TW (1)	TWI799417B (en)
UY (1)	UY37747A (en)
WO (1)	WO2018215964A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102473898B1 (en)	2017-05-26	2022-12-07	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	Biopharmaceutical compositions and related methods
US11613571B2 (en)	2018-05-23	2023-03-28	Glaxosmithkline Intellectual Property Development Limited	Biopharmaceutical compositions comprising antibody variants
WO2020119728A1 (en) *	2018-12-12	2020-06-18	尚华科创投资管理（江苏）有限公司	Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
JP2024500912A (en) *	2020-12-22	2024-01-10	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	Interleukin-5 binding protein dosing regimen
WO2022136209A1 (en)	2020-12-22	2022-06-30	Glaxosmithkline Intellectual Property Development Limited	Interleukin 5 binding protein dosage regimen
WO2023099668A1 (en)	2021-12-03	2023-06-08	Glaxosmithkline Intellectual Property Development Limited	Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
WO2025238121A1 (en)	2024-05-17	2025-11-20	Glaxosmithkline Intellectual Property Development Limited	Anti-il-5 antibody in the treatment of asthma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
NZ301916A (en) *	1994-12-23	1999-05-28	Smithkline Beecham Corp	Monoclonal antibodies to il-5 for use as antagonists to il-5 related disorders
AU2008201419C1 (en)	2000-12-12	2018-01-18	Board Of Regents, The University Of Texas System	Molecules with extended half-lives, compositions and uses thereof
HRP20140789T1 (en)	2007-04-30	2014-10-10	Glaxosmithkline Llc	PROCEDURES FOR THE APPLICATION OF ANTIBODIES AGAINST IL-5
KR20100134702A (en)	2008-03-28	2010-12-23	글락소스미스클라인 엘엘씨	How to treat
RU2620071C2 (en) *	2010-11-17	2017-05-22	Чугаи Сеияку Кабушики Каиша	Multispecific antigen-binding molecule with alternate function to blood coagulation factor viii function
BR112013016235B1 (en) *	2010-12-22	2020-03-31	Cephalon Australia Pty Ltd	ISOLATED ANTIBODY, USE OF AN ANTIBODY, NUCLEIC ACID, TRANSFORMED CELL AND PHARMACEUTICAL COMPOSITION
US8790651B2 (en) *	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody
KR20250086801A (en)	2015-08-24	2025-06-13	글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드	Biopharmaceutical compositions
AR110564A1 (en)	2016-12-23	2019-04-10	Cephalon Inc	ANTI-IL-5 ANTIBODIES
KR102473898B1 (en)	2017-05-26	2022-12-07	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	Biopharmaceutical compositions and related methods
US11613571B2 (en) *	2018-05-23	2023-03-28	Glaxosmithkline Intellectual Property Development Limited	Biopharmaceutical compositions comprising antibody variants

2018
- 2018-05-24 KR KR1020197037587A patent/KR102473898B1/en active Active
- 2018-05-24 CN CN202311013236.4A patent/CN117018188A/en active Pending
- 2018-05-24 CN CN202311013609.8A patent/CN117018189A/en active Pending
- 2018-05-24 CN CN201880046323.0A patent/CN110891968B/en active Active
- 2018-05-24 AU AU2018273174A patent/AU2018273174B2/en active Active
- 2018-05-24 UY UY0001037747A patent/UY37747A/en unknown
- 2018-05-24 SG SG10201913497XA patent/SG10201913497XA/en unknown
- 2018-05-24 JP JP2019565279A patent/JP7224304B2/en active Active
- 2018-05-24 EA EA201992802A patent/EA201992802A1/en unknown
- 2018-05-24 CN CN202311014554.2A patent/CN117100853A/en active Pending
- 2018-05-24 NZ NZ760380A patent/NZ760380A/en unknown
- 2018-05-24 MX MX2019014105A patent/MX2019014105A/en unknown
- 2018-05-24 PE PE2019002461A patent/PE20191844A1/en unknown
- 2018-05-24 TW TW107117675A patent/TWI799417B/en active
- 2018-05-24 US US15/987,942 patent/US10787509B2/en active Active
- 2018-05-24 WO PCT/IB2018/053683 patent/WO2018215964A1/en not_active Ceased
- 2018-05-24 BR BR112019024884-6A patent/BR112019024884A2/en unknown
- 2018-05-24 AR ARP180101401A patent/AR111764A1/en unknown
- 2018-05-24 CA CA3064522A patent/CA3064522A1/en active Pending
- 2018-05-24 CN CN202311013988.0A patent/CN117018190A/en active Pending
- 2018-05-24 IL IL270719A patent/IL270719B2/en unknown
- 2018-05-24 EP EP18732488.4A patent/EP3630824A1/en active Pending
- 2018-05-24 CR CR20190541A patent/CR20190541A/en unknown
- 2018-05-24 MY MYPI2019006883A patent/MY200912A/en unknown
2019
- 2019-11-21 PH PH12019502619A patent/PH12019502619A1/en unknown
- 2019-11-22 DO DO2019000297A patent/DOP2019000297A/en unknown
- 2019-11-22 CL CL2019003418A patent/CL2019003418A1/en unknown
- 2019-11-26 CO CONC2019/0013245A patent/CO2019013245A2/en unknown
2020
- 2020-08-07 US US16/988,257 patent/US11976113B2/en active Active
2021
- 2021-09-17 AU AU2021232807A patent/AU2021232807A1/en not_active Abandoned
2023
- 2023-01-31 JP JP2023013628A patent/JP7521022B2/en active Active
2024
- 2024-03-22 US US18/613,481 patent/US20240417456A1/en active Pending

Also Published As

Publication number	Publication date
CN117018189A (en)	2023-11-10
JP7224304B2 (en)	2023-02-17
TWI799417B (en)	2023-04-21
CN110891968B (en)	2023-08-29
JP2023058546A (en)	2023-04-25
CO2019013245A2 (en)	2020-01-17
TW201908334A (en)	2019-03-01
DOP2019000297A (en)	2020-02-16
EA201992802A1 (en)	2020-07-10
IL270719B2 (en)	2024-11-01
US20240417456A1 (en)	2024-12-19
KR20200010401A (en)	2020-01-30
US20210017269A1 (en)	2021-01-21
UY37747A (en)	2019-01-02
NZ760380A (en)	2023-07-28
BR112019024884A2 (en)	2020-06-16
CN117100853A (en)	2023-11-24
PE20191844A1 (en)	2019-12-31
CL2019003418A1 (en)	2020-03-20
MY200912A (en)	2024-01-23
CN110891968A (en)	2020-03-17
JP2020521465A (en)	2020-07-27
AU2021232807A1 (en)	2021-10-14
IL270719A (en)	2020-01-30
US10787509B2 (en)	2020-09-29
US11976113B2 (en)	2024-05-07
CN117018190A (en)	2023-11-10
IL270719B1 (en)	2024-07-01
JP7521022B2 (en)	2024-07-23
KR102473898B1 (en)	2022-12-07
PH12019502619A1 (en)	2020-06-15
AU2018273174A1 (en)	2019-12-05
CN117018188A (en)	2023-11-10
US20180340023A1 (en)	2018-11-29
AR111764A1 (en)	2019-08-14
CR20190541A (en)	2020-01-20
EP3630824A1 (en)	2020-04-08
WO2018215964A1 (en)	2018-11-29
CA3064522A1 (en)	2018-11-29
MX2019014105A (en)	2020-02-07
AU2018273174B2 (en)	2021-10-14

Publication	Publication Date	Title
IL268970A (en)	2019-10-31	Novel compositions and methods
IL265844A (en)	2019-06-30	Anti-lag-3 antibodies and compositions
IL280134A (en)	2021-03-01	Anti-cd112r compositions and methods
IL262176A (en)	2018-11-29	Anti-tim-3 antibodies and compositions
IL256295A (en)	2018-02-28	Anti-ntb-a antibodies and related compositions and methods
HUE065174T2 (en)	2024-05-28	Hla-based methods and compositions and uses thereof
GB2546350B (en)	2019-12-04	Compositions and methods
GB201807325D0 (en)	2018-06-20	Compositions and methods
GB201718876D0 (en)	2017-12-27	Antithrombin-heparin compositions and methods
GB202201861D0 (en)	2022-03-30	Novel methods and compositions
GB201705091D0 (en)	2017-05-17	Compositions and methods and uses relating thereto
SG10201913497XA (en)	2020-02-27	Biopharmaceutical compositions and related methods
SG11202104448WA (en)	2021-05-28	Compositions and methods
IL274524A (en)	2020-06-30	Compositions and methods for aquaculturing
ZA202004533B (en)	2021-09-29	Skin-brightening compositions and methods
GB201817444D0 (en)	2018-12-12	Methods and compositions
GB201715820D0 (en)	2017-11-15	Compositions and methods
GB201705626D0 (en)	2017-05-24	Compositions and methods
GB201819987D0 (en)	2019-01-23	Methods and compositions
GB201512996D0 (en)	2015-09-09	Compositions and methods
ZA201807665B (en)	2020-02-26	Methods and compositions
GB201804092D0 (en)	2018-04-25	Methods and compositions
GB201703975D0 (en)	2017-04-26	Composition and methods
GB201514413D0 (en)	2015-09-30	Compositions and methods
HK40019757A (en)	2020-10-16	Biopharmaceutical compositions and related methods